Stem Cell Therapy Market (By Product: Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs), Very Small Embryonic Like Stem Cells; By Therapy Type; By Application; By Technology; By End User) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Stem Cell Therapy market size was estimated at USD 9.87 billion in 2021 and is expected to surpass around USD 31.41 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 13.73% during the forecast period 2022 to 2030.

Key Takeaways:

  • By product, the adult stem cells (ASCs) segment has reached 85.9% revenue share in 2021
  • The induced pluripotent stem cells (iPSCs) segment is predicted to grow at a CAGR of 9.5% between 2022 to 2030
  • By application, the regenerative medicine segment has garnered 91% in 2021
  • The drug discovery and development application segment is projected to grow at a CAGR of 9.5% from 2022 to 2030
  • By therapy, allogenic stem cell therapy has hit market share of 58.5% in 2021
  • North America accounted for the largest market share of 53% in 2021
  • Asia Pacific is expected to grow at a CAGR of 9.2% between 2022 to 2030

The factors contributing to the growth include increasing demand for biologics, technological advancement in stem cell therapeutics, and a growing focus on the development of personalized medicines. The increasing focus on the treatment of neurological disorders contributes to the market expansion. According to the World Health Organization (WHO), around 7.1% of the total global burden of diseases is cerebrovascular diseases and neurological disorders. Hence, companies are conducting basic research and preclinical trials for testing the regenerative capacity of stem cells in the treatment of neurological conditions.

Companies are receiving robust funding for the development of cellular therapies for cancer, which is anticipated to supplement the market growth. For instance, in February 2021, Notch Therapeutics, Inc. received funding of USD 85 million for developing induced pluripotent therapies for cancer. The investment will support the development of the company’s iPSC-derived T cell-based therapeutic candidates and expanding the application of their proprietary Engineered Thymic Niche (ETN) platform.

The increasing focus on regenerative medicines is further driving the market growth. The iPSCs are gaining popularity for the development of personalized cellular therapies and are creating new opportunities for regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can help in the treatment of placenta complications during pregnancy.

The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells. The discovery will facilitate in developing a model human placenta in vitro and enabling a pathway for future cell therapies. The administration of cell therapy demonstrated positive results in the treatment of COVID-19 patients, which is further contributing to the market growth. In January 2020, a group of researchers used stem cell treatment on patients in Beijing, China for checking its effectiveness against COVID-19.

The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response. However, to date, there are no MSCs that are approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 owing to insufficient data on their role in treating COVID-19.

Report Scope of the Stem Cell Therapy Market

Report Coverage

Details

Market Size in 2022

USD 11.22 Billion

Market Size by 2030

USD 31.41 Billion

Growth Rate from 2022 to 2030

CAGR of 13.73%

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Product, Therapy Type, Application, Technology, End User, Geography

Companies Mentioned

Caladrius, CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank, Opexa Therapeutics, Inc., Pluristem Therapeutics Inc, STEMCELL Technologies Inc., Biovault family, Precious Cells International, Ltd, Mesoblast Ltd,  Seneca Biopharmaceuticals, Inc.

 

Global Stem Cell Therapy Market Dynamics

DRIVER: Availability of funding for stem cell research

Stem cell research funding has strengthened in the past few years attributed to the need for novel therapeutic interventions in patients with cardiovascular, neurological, and autoimmune disorders. The NIH funding for stem cell research reached its highest peak in 2018 and has shown a year-on-year growth of more than 5% in the stem cell research funding each year. This trend is expected continue with the increase in funding initiatives announced in 2021 For instance, in September 2021, the California Institute for Regenerative Medicine granted a funding of USD 31 million to Stanford research for launching first-in-human trials of stem cells in the treatment of heart failure, stroke, spinal cord tumor.

RESTRAINTS: Ethical concerns related to embryonic stem cells

Studies exploring the therapeutic potential of embryonic stem cells (ESC) are associated with various ethical issues attributed to the destruction of human embryo. Lack of proper federal policies that define what can be funded in the embryo-based stem cell research or therapy development may restrain the market expansion in future to a certain extent. In addition, complexities of regulations in this area require federal guidelines that can support researchers, scientists, and pharmaceutical companies to develop ESC therapy and further facilitate its commercialization.

Product Insights

The adult stem cells (ASCs) segment dominated the market in 2021, with a share of 85.9%. The primary factors that contributed to the dominance of the segment include the presence of minimal controversial issues concerning ethics, immune-rejection, and tumorigenesis. The application of ASCs in regenerative medicines can be further attributed to the segment growth. The ASCs bioprocessing for regenerative medicine is anticipated to face challenges during process development.

ASCs are further segmented into hematopoietic stem cells, mesenchymal stem cells (MSCs), neural stem cells, and epithelial/skin stem cells. The MSC segment is anticipated to expand at the fastest CAGR during the forecast period owing to their potential use in autologous transplantation, large clinical trials conducted that marked its application in the treatment of various diseases and extensive research to explore its therapeutic applications.

The induced pluripotent stem cells (iPSCs) segment is expected to witness a substantial CAGR of 9.5% through 2021-2028 owing to increasing investment for developing regenerative medicines using iPSC, ensured reproducibility and maintenance, capable of differentiation into all the cell types and high proliferative ability. Owing to the gaining importance of iPSCs in the treatment of various diseases, companies are expanding services associated with these.

Application Insights

The application segment can be further divided into regenerative medicine and drug discovery and development. Regenerative medicine is held the largest market share of 91% in 2021 owing to increasing approval for stem cell therapies clinical trials targeting different diseases. For instance, in June 2021, Longeveron LLC announced Japan’s Pharmaceutical and Medical Devices Agency (PMDA) approval for the starting Phase 2 clinical trial for evaluating the safety and efficacy of their Mesenchymal Stem Cells (LMSCs) that can be used for treating aging frailty.

Besides, several governments are investing heavily in the development of regenerative medicines. For instance, in March 2020, the Government of Canada invested around USD 6.9 million for regenerative medicine research. The funds will support 4 clinical trials and 9 translational projects aimed to bring new therapies in the regenerative medicine sector. The regenerative medicines developed will help in the treatment of various heart diseases, blood disorders, vision loss, and diabetes.  

The drug discovery and development segment is expected to witness a lucrative CAGR of 9.5% from 2022 to 2030. The market products are witnessing increased penetration across drug discovery as it is useful in studying human disease etiology, identifying pathological mechanisms, and developing therapeutic strategies for tackling various diseases. The iPSC-based models are preferred over phenotypic screening, as they can mimic molecular and cellular phenotypes of patients. By utilizing these, pharmaceutical companies can test hypothesized drug mechanisms in vitro in a cost-effective manner before conducting clinical trials.

Therapy Insights

Allogenic stem cell therapy accounted for the largest revenue share of 58.5% in 2021. Allogeneic cells are extensively used owing to their graft vs-cancer effect for the treatment of cancer. With the help of this effect stem cells from the donor can use their immune system cell for killing cancer cells. The provoked immune system response by the donor is comparatively stronger than the recipient’s immune system. Besides, these are commonly used for treating different types of cancers such as lymphomas, leukemias, and myelomas.

Autologous therapy is expected to expand at a lucrative CAGR during the forecast period. The growth can be attributed to the advantages such as few changes of graft rejection hence it is associated with fewer complications. The other factors contributing to the growth of the segment consist of high survival rate of patients, affordability, no necessity for HLA typing for matching donor, low risk, and application of these cells can proceed without being tested in clinical trials or facing stringent manufacturing standards.

Regional Insights

North America accounted for the largest market share of 53% in 2021; growth in the region can be attributed to several factors such as the presence of key players engaged in developing stem cell therapies, advanced healthcare infrastructure, extensive R&D, supportive reforms from healthcare organizations and strong reimbursement policies. The U.S. is the leading country in the region owing to government initiatives and high research activities in the country.

Healthcare organizations are promoting the use of cellular therapies for emerging diseases. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) authorized a clinical trial exploratory efficacy study that used umbilical cord-derived MSCs for prevention of the life-threatening lung inflammation in COVID-19 patients.

Asia Pacific is expected to expand at the fastest CAGR of 9.2% during the forecast year owing to the increasing development of stem cell-based therapies, government initiatives for developing regenerative medicines, the setup of several stem cell banks, and increasing clinical trials for regenerative medicines in the region. For instance, in July 2020, MEDIPOST announced the results for NEUROSTEM’s phase 1/2a study. It is an investigational stem cell therapy that can be used for treating Alzheimer’s disease.

Some of the prominent players in the Stem Cell Therapy Market include:

  • Caladrius
  • CELGENE CORPORATION
  • ReNeuron Group plc
  • Virgin Health Bank
  • Opexa Therapeutics, Inc.
  • Pluristem Therapeutics Inc
  • STEMCELL Technologies Inc.
  • Biovault family
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Seneca Biopharmaceuticals, Inc.

 Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Stem Cell Therapy market

By Product

  • Adult Stem Cells (ASCs)
    • Hematopoietic
    • Mesenchymal
    • Neural
    • Epithelial/Skin
    • Others
  • Human Embryonic Stem Cells (HESCs)
  • Induced Pluripotent Stem Cells (iPSCs)
  • Very Small Embryonic Like Stem Cells

By Therapy Type

  • Autologous
  • Allergenic

By Application

  • Regenerative Medicine
    • Neurology
    • Orthopedics
    • Oncology
    • Hematology
    • Cardiovascular and Myocardial Infraction
    • Injuries
    • Diabetes
    • Liver Disorder
    • Incontinence
    • Others
  • Drug Discovery and Development

By Technology

  • Cell Acquiition
    • Bone Marrow Harvest
    • Umbilical Blood Cord
    • Apheresis
  • Cell Production
    • Therapeutic Cloning
    • In-vitro Fertilization
    • Cell Culture
    • Isolation
  • Cryopreservation
  • Expansion and Sub-Culture

By End User

  • Hospitals
  • Research institutes
  • surgical institutes
  • Orders

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Stem Cell Therapy industry analysis from 2022 to 2030 to identify the prevailing Stem Cell Therapy industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Stem Cell Therapy industry segmentation assists to determine the prevailing market opportunities.
  • <li class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: norm